A new trading day began on Tuesday, with AbCellera Biologics Inc (NASDAQ: ABCL) stock price up 10.51% from the previous day of trading, before settling in for the closing price of $3.33. ABCL’s price has ranged from $1.89 to $3.68 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -107.74%. Meanwhile, its annual earnings per share averaged -10.77%. With a float of $223.95 million, this company’s outstanding shares have now reached $298.36 million.
Considering the fact that the conglomerate employs 596 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is -474.21%, operating margin of -1579.18%, and the pretax margin is -911.24%.
AbCellera Biologics Inc (ABCL) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of AbCellera Biologics Inc is 24.97%, while institutional ownership is 41.08%.
AbCellera Biologics Inc (ABCL) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -10.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.83% during the next five years compared to -107.74% drop over the previous five years of trading.
AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators
Here are AbCellera Biologics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 47.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.57, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of AbCellera Biologics Inc (ABCL)
Compared to the last year’s volume of 4.62 million, its volume of 7.66 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 83.79%.
During the past 100 days, AbCellera Biologics Inc’s (ABCL) raw stochastic average was set at 95.21%, which indicates a significant increase from 94.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.32% in the past 14 days, which was higher than the 77.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.46, while its 200-day Moving Average is $2.68. Nevertheless, the first resistance level for the watch stands at $3.85 in the near term. At $4.02, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.27. If the price goes on to break the first support level at $3.43, it is likely to go to the next support level at $3.18. Now, if the price goes above the second support level, the third support stands at $3.01.
AbCellera Biologics Inc (NASDAQ: ABCL) Key Stats
With a market capitalization of 1.10 billion, the company has a total of 298,424K Shares Outstanding. Currently, annual sales are 28,830 K while annual income is -162,860 K. The company’s previous quarter sales were 4,240 K while its latest quarter income was -45,620 K.
